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Abstract: Biofilms formed by Staphylococcus aureus is a serious complication to the use of medical
implants. A central part of the pathogenesis relies on S. aureus’ ability to adhere to host extracellular
matrix proteins, which adsorb to medical implants and stimulate biofilm formation. Being coagulase
positive, S. aureus furthermore induces formation of fibrin fibers from fibrinogen in the blood.
Consequently, we hypothesized that fibrin is a key component of the extracellular matrix of S. aureus
biofilms under in vivo conditions, and that the recalcitrance of biofilm infections can be overcome
by combining antibiotic treatment with a fibrinolytic drug. We quantified S. aureus USA300 biofilms
grown on peg-lids in brain heart infusion (BHI) broth with 0%–50% human plasma. Young (2 h) and
mature (24 h) biofilms were then treated with streptokinase to determine if this lead to dispersal.
Then, the minimal biofilm eradication concentration (MBEC) of 24 h old biofilms was measured for
vancomycin and daptomycin alone or in combination with 10 µg/mL rifampicin in the presence or
absence of streptokinase in the antibiotic treatment step. Finally, biofilms were visualized by confocal
laser scanning microscopy. Addition of human plasma stimulated biofilm formation in BHI in a
dose-dependent manner, and biofilms could be partially dispersed by streptokinase. The biofilms
could be eradicated with physiologically relevant concentrations of streptokinase in combination
with rifampicin and vancomycin or daptomycin, which are commonly used antibiotics for treatment
of S. aureus infections. Fibronolytic drugs have been used to treat thromboembolic events for decades,
and our findings suggest that their use against biofilm infections has the potential to improve the
efficacy of antibiotics in treatment of S. aureus biofilm infections.
Keywords: USA300; biofilm; human plasma; fibrinolysis; MBEC
1. Introduction
A key aspect of pathogenesis by Staphylococcus aureus is the formation of biofilms [1] by
interacting with mammalian extracellular matrix (ECM) molecules on ECM-covered surfaces in the
body [2,3]. S. aureus possesses an array of cell wall-anchored proteins responsible for these specific
receptor-ligand interactions, collectively called “microbial surface components recognizing adhesive
matrix molecules” [2]. These include Clumping factor A and B and SdrE which bind to fibrinogen and
complement factors [4–6], the fibronectin- and fibrinogen-binding proteins FnBPA and FnBPB [7–9],
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the fibronectin-binding proteins Ebh, the collagen-binding Collagen Adhesin (Cna) [10], and many
other proteins for which the ligands are yet to be described [2]. In addition to these receptor-ligand
interactions, a recent study also demonstrated that cell-surface proteins containing particular domains
with internal thioester bonds could react with fibrinogen to form a covalent interaction, and that many
pathogens, including S. aureus, contain cell surface proteins with similar domains [11].
S. aureus biofilm infections are often localized to bones, soft tissues, heart valves [12–14],
or implants which are quickly covered with ECM molecules following implantation [15–17].
After adhesion to ECM molecules, S. aureus induces coagulation, which results in the formation of
a three dimensional matrix of fibrin around the cells. S. aureus secretes two proteins that induce
coagulation: coagulase and von Willebrand factor-binding protein. These proteins highjack the
coagulation cascade by binding to prothrombin, which results in the formation of staphylothrombin
that converts fibrinogen to fibrin. Conversely, S. aureus can also induce degradation of fibrin
by secreting staphylokinase, which activates plasminogen to plasmin—a serine protease capable
of fibrinolysis.
The addition of human plasma facilitates coagulation during growth of S. aureus in
laboratory media and therefore greatly stimulates biofilm formation in vitro [18,19]. In vivo, the
production of coagulase and the fibrin-binding Clumping factor A and FnBPs are reported to be
particularly critical for biofilm formation [20]. Along with the reported lack of biofilm formation in
staphylokinase-overexpressing strains [21], these findings testify to the key role of fibrin in the S. aureus
biofilm matrix in vivo.
The formation of a fibrin matrix provides S. aureus with an ideal defense mechanism against
immune cells [22,23], and S. aureus biofilms are also more recalcitrant to antibiotic therapy, both in vitro
and in vivo [24–26]. The antibiotic dosage required for eradication of a mature S. aureus biofilms in vitro
are in the range of 256–2048 mg/L for vancomycin, daptomycin, and other relevant anti-staphylococcal
drugs, which far exceeds the concentration that can be achieved in vivo [25,27]. This recalcitrance
to antibiotic treatment is due to a combination of several factors, including the reduced penetration
and lower diffusion coefficient of many antibiotics in the biofilm, which has been demonstrated for
S. aureus biofilms with, for example, vancomycin, oxacillin, and cefotaxime [28,29].
Due to the low efficacy of antimicrobials against cells within biofilms, a combined approach
is gaining increasing interest, where the matrix of biofilms is targeted to disperse the biofilm while
simultaneously applying antimicrobials. Enzymatic degradation of matrix polysaccharides or eDNA
has been applied with varying success in vitro [30–32]. However, the knowledge that host-derived
components, particularly fibrin, are more important components of the S. aureus biofilm matrix in vivo
suggests these might be more efficacious targets.
Only a handful of studies have investigated this idea so far. Activation of plasminogen by
fibrinolytic drugs is used to treat blood clots, and the same principle could be applied to dissolve
the fibrin of S. aureus biofilms. Nemoto et al. were the first to demonstrate that 10,000 U/mL of the
fibrinolytic drug Varidase (streptokinase) given concurrently with ofloxacin enhanced the efficacy of
antibiotic treatment of in vitro grown S. aureus biofilms [33]. Recently, several studies have shown that
prevention of fibrin formation leads to decreased biofilm formation and higher antibiotic susceptibility
of in vivo grown S. aureus biofilms. This was shown by preventing S. aureus-mediated coagulation by
adding a thrombin inhibitor to jugular vein catheters in mice [34], or by adding human plasminogen
to a staphylokinase-overexpressing S. aureus strain, which led to fibrin dissolution as a result of
staphylokinase-mediated activation of plasminogen [20]. Biofilm formation was also reduced by
coating implant surfaces with the human tissue plasminogen activator (tPA), and the biofilms that
did form were more susceptible to antibiotics [35]. These are encouraging results for the possibility
of preventing biofilm formation to avoid acute infections on new implants. However, the treatment
of biofilm infections that occur years after implantation is even more critical. Zapotoczna et al. [19]
showed that S. aureus biofilms formed in vivo in a catheter inserted in the jugular vein in a rat model
could be dispersed ex vivo by treating the biofilm with nattokinase. It is, however, not known if
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the same effect can be obtained in vivo, and which antibiotic concentration is needed to eradicate
the biofilm.
The aim of this study was therefore to determine if S. aureus USA 300 biofilms could be eradicated
by combining streptokinase with selected antibiotics at physiologically relevant concentrations. We
grew S. aureus biofilms in a high throughput peg-lid biofilm assay and quantified the amount of biofilm
after growth in brain heart infusion (BHI) amended with different concentrations of human plasma.
We then determined the effect of streptokinase treatment on biofilm dispersal, and on the minimal
biofilm eradication concentration (MBEC) of antibiotics provided as single drugs or in combinations.
Finally, confocal laser scanning microscopy visualized the biofilm architecture and viability.
2. Materials and Methods
2.1. Human Plasma Extraction
Human plasma was generously provided by the Blood Bank, Aarhus University Hospital.
Identification of the individual donors was not possible. Donors had signed a generalized consent
form and since the blood was not to be used in studies involving screening for undiagnosed conditions,
further ethical approval was not necessary. Blood from healthy donors was stabilized in 10 mL tubes
(BD Vacutainer, Beckton Dickinson, Albertslund, Denmark) coated with EDTA (1.8 mg EDTA/mL
blood). Plasma was separated from whole blood by centrifugation at 6000× g for 10 min at 5 ◦C.
Subsequently, plasma from more than 100 different donors was pooled to ensure reproducibility.
2.2. Quantification of Human Plasma’s Effect on Biofilm Formation
S. aureus USA300 was stored in 50% glycerol at −80 ◦C. Prior to each experiment, 1 µL was
streaked on Tryptic Soy Agar (TSA) (Sigma-Aldrich, Copenhagen, Denmark) and incubated at 37 ◦C
until colonies formed, and then stored at 5 ◦C for up to one month. A single colony was used to
inoculate 10 mL 3.7% Brain-Heart Infusion broth (BHI) (Sigma-Aldrich, Copenhagen, Denmark) in
Erlenmeyer flasks and incubated at 37 ◦C and subjected to 100 rpm shaking for 16–18 h. The overnight
culture was then adjusted to OD600 = 5.0 in fresh BHI.
Biofilms were grown in a modified Calgary Biofilm Device protocol [36]. We used flat-bottom
96-well microtiter plates (NUNC 161093, Thermo Fisher Scientific, Hvidovre, Denmark) and matching
peg-lids (NUNC-TSP 445497, Thermo Fisher Scientific). Each peg-lid was pre-conditioned by inserting
it into a 96-well plate containing 180 µL/well 3.7% BHI enriched with 50% human plasma for 30 min
at 37 ◦C. Peg-lids were then transferred into a new microtiter plate containing 20 µL of the overnight
culture of S. aureus USA300 prepared as described above, and 180 µL of BHI enriched with either 0%,
5%, 10%, 25%, or 50% plasma. After 2 h incubation at 37 ◦C, the peg-lids, now covered with a biofilm,
were transferred back to the microtiter plates used for pre-conditioning and incubated for 24 h at 37 ◦C
to allow further growth and maturation of the biofilm. To simplify nomenclature, we will refer to the
2 h biofilm as “immature” and the 2 + 24 h as “mature” in the following sections.
The amount of biofilm was then quantified using the crystal violet assay as follows: Each peg-lid
with biofilm was dried at 37 ◦C for 30–60 min and then transferred to a 96-well plate containing
200 µL/well freshly prepared 0.5% crystal violet solution (Sigma-Aldrich) in demineralized water, and
left to stain at room temperature for 10 min. Excess stain was removed from the peg-lid by gently
rinsing it three times by submersion in demineralized water. After rinsing, the lid was transferred to a
new 96-well plate containing 200 µL/well 96% ethanol. After 10 min, the peg-lid was discarded, and the
optical density of the crystal violet-stained ethanol solutions was measured at 585 nm. This experiment
was carried out with a minimum of 8 replicates.
2.3. Biofilm Dispersal with Streptokinase
The peg-lid with S. aureus USA300 biofilm (prepared as described above using BHI with 50%
plasma) was transferred to a 96-well plate containing 200 µL/well of freshly prepared (up to 5 min
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in advance) streptokinase (Sigma-Aldrich) in BHI and incubated for 1 h at 37 ◦C. The amount of the
biofilm was then quantified using the crystal violet assay as described above. Treatment of immature
biofilms was performed with 0, 50, 100, and 150 U/mL streptokinase, while mature biofilms were
treated with 500 U/mL streptokinase in BHI. This experiment was performed with a minimum of
three replicates.
2.4. MBEC of Antibiotics Combined with Streptokinase
Mature biofilms were prepared as described above using BHI with 50% plasma or tryptic
soy broth (TSB) (Fluka Analytical). Antibiotics were dissolved into BHI, and serially diluted
(two-fold in each step) in a 96-well plate, such that concentration ranges were 0–2048 µg/mL for
vancomycin (Sigma-Aldrich) and daptomycin (Cubicin, Novartis, Denmark). The concentration of
rifampicin (Eramfat, Riemser Pharma GmbH, Greifswald, Germany) was, however, kept constant
at 10 µg/mL. Peg-lids with mature biofilms were transferred to the plate containing BHI with
antibiotics, or antibiotics with 500 U/mL streptokinase (Sigma-Aldrich), and incubated for 24 h
at 37 ◦C. The combination of antibiotics tested were: vancomycin alone, vancomycin with rifampicin,
daptomycin alone, and daptomycin with rifampicin.
After antibiotic exposure, biofilms were rinsed by gently submerging the lid in a 96-well plate
containing BHI three times and were then transferred to a “recovery plate” containing 500 U/mL
streptokinase solution in BHI, and incubated for 24 h at 37 ◦C. The absence of viable cells among the
bacteria detached from the biofilm during incubation with antibiotics and streptokinase was confirmed
by spotting 10 µL to a fresh agar plate and incubating overnight at 37 ◦C. Bacteria-free pegs were
used as blanks, and pegs with biofilms that had not been treated with antibiotics were used as growth
controls. After the incubation, peg-lids were discarded and planktonic growth was assessed in the
wells by transferring 5 µL from wells without visible growth to TSA and incubating for 24 h 37 ◦C
before assessing the presence of colonies. The experiment was performed with a minimum of eight
replicates, and the MBEC value was determined as the antibiotic concentration resulting in the absence
of viable cells in the recovery plate in at least five out of eight replicates.
It should be noted that streptokinase is usually not included in the recovery plates in standard
MBEC protocols. However, in control experiments we found no growth in the recovery plates, even
in the absence of antibiotics. Hence the S. aureus cells were so firmly attached in the biofilm that
no planktonic growth resulted from transferring the biofilm to fresh BHI. With streptokinase in the
recovery media, all controls were positive for planktonic growth (see results section).
2.5. Confocal Laser Scanning Microscopy (CLSM)
Microtiter plates for microscopy (Product # 89621, Ibidi, Munich, Germany) were pre-conditioned
in 180 µL modified BHI-plasma medium containing 78 µL plasma, 90 µL BHI, and 12 µL
Alexa Fluor® 647-conjugated fibrinogen (Thermo Fisher Scientific) in sodium bicarbonate, pH 8.3.
The resulting concentration of Alexa Fluor-conjugated fibrinogen was 200 µg/mL, which corresponds
to approximately 20% of the total fibrinogen expected to be present in the media. The plates were
incubated for 30 min at 37 ◦C before the addition of 20 µL of overnight culture (adjusted to OD600 = 5)
was added to each well (final OD600 = 0.50, final volume = 200 µL/well) and incubated for 2 h at
37 ◦C. The medium was then gently removed by aspiration and replaced with 300 µL of the modified
BHI-plasma medium. The plate was then incubated for 24 h at 37 ◦C to generate mature biofilms.
The biofilms were then incubated for another 24 h at 37 ◦C in fresh media (modified BHI-plasma
medium), or media amended with 4 µg/mL vancomycin and 10 µg/mL rifampicin, or media amended
with 500 U/ml streptokinase in addition to the antibiotics.
CLSM imaging was done with a Zeiss LSM700 confocal laser scanning microscope
(Zeiss, Jena, Germany). The medium was removed, and each well was gently rinsed five times
in 300 µL sterile phosphate buffered saline (PBS) before adding 150 µL PBS containing 10 µM of the
membrane-permeant DNA-binding stain SYTO 41 (Thermo Fisher Scientific) for live-cell imaging,
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and 2 µM of the membrane-impermeant DNA-binding stain TOTO®-1 (Thermo Fisher Scientific) for
dead cell imaging. The biofilms were incubated at room temperature for 45–60 min with the staining
solution before imaging. SYTO 41 and Alexa Fluor® 647 were captured in one track with excitation by
the 405 nm and 635 nm lasers and splitting the emission to the two photomultipliers at 600 nm, and
TOTO®-1 was then captured by excitation with the 488 nm laser in a second track.
2.6. Statistics
Statistical tests were done using the GraphPad Prism 5.0f (Graphpad Software, La Jolla, CA, USA).
The data was plotted to assess normal distribution, and since the data follow a normal distribution, all
tests were done using parametric testing (Student’s t-test).
First-order and zero order equations were fitted to the data from crystal violet staining of biofilms
to determine the dose-response effect of adding human plasma to BHI, and of treating pre-formed
biofilms with increasing concentrations of streptokinase.
3. Results
3.1. Human Plasma Promotes Formation of Biofilms That Can Be Dispersed by Streptokinase Treatment
S. aureus USA300 formed very little biofilm in BHI, but the addition of increasing concentrations
of plasma led to a dose-dependent increase in biofilm formation (Figure 1). The amount of biofilm
formed increased linearly (R2 = 0.96) at plasma concentrations up to 25% and then leveled off,
indicating that the availability of plasma proteins was the limiting factor for biofilm formation at
plasma concentrations below 25%.
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Figure 1. Mean biofilm biomass (±SD, n = 8), measured by crystal violet staining. USA300 formed
very little biofilm in pure brain heart infusion (BHI), but the addition of human plasma led to increased
biofilm formation in a dose-dependent manner. * significantly different (p < 0.001).
Immature (2 h old) biofilms could be partially dispersed by 1 h streptokinase treatment (Figure 2A).
The amount of biofilm decreased in a dose-dependent manner after treatment with 50, 100, or 150 U/mL
streptokinase (p < 0.05). Mature (24 h old) biofilms could also be dispersed, but required higher
streptokinase concentrations. Treatment with 500 U/mL lead to a 22-fold reduction of biomass from
25.8 to 1.2 (Figure 2B).
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Figure 2. Mean biofilm biomass (± SD, n = 8), measured by crystal violet staining after incubation of 2 h
old (A) and 24 h old (B) biofilms with streptokinase for 24 h. Increasing concentrations of streptokinase
resulted in a dose dependent decrease in biomass. A single high dose was applied to 24 h old biofilms,
resulting in almost complete biofilm dispersal. * significantly di fe ent (p < 0.001).
3.2. Streptokinase Treatment Lowers the MBEC to Clinically Relevant Levels
The addition of streptokinase during antibiotic treatment dramatically increased the susceptibility
of biofilms to antibiotics, resulting in lower MBEC values (Table 1). The most pronounced effect
was observed when streptokinase was applied together with a combination of rifampicin and either
vancomycin or daptomycin. The combination of streptokinase and two antibiotics lowered the MBEC
to a level that can safely be obtained in vivo (Table 1).
Table 1. Minimal biofilm eradication concentration (MBEC) against biofilms of S. aureus USA300
grown for 24 h in BHI with 50% plasma and incubated with antibiotics in the presence or absence of
streptokinase. Rifampicin was added as a fixed dosage of 10 mg/L.
Antibiotic MBEC (−Streptokinase) (mg/L) MBEC (+Streptokinase) (mg/L)
Daptomycin 1024 1024
Daptomycin + rifampicin 64 <4
Vancomycin 128 64
Vancomycin + rifampicin 64 4
We hypothesized that fibrin was a major part of the biofilm matrix, and that the effect of
streptokinase was due to fibrinolysis. We therefore visualized the biofilm architecture, including
the fibrin component. S. aureus USA300 biofilms were grown for 24 h in BHI supplemented with
human plasma and Alexa Fluor® conjugated fibrinogen before transferring and incubating the biofilms
for an additional 24 h in either fresh media, or media supplemented with antibiotics, streptokinase, or
both. CLSM imaging showed biofilms consisting of aggregates of cells with fibrin fibers extending
more than 20 µm from the cell surface (Figure 3A). The addition of 4 mg/L vancomycin and 10 mg/L
rifampic n did not result in visible losses of biomass or viable cells (F gure 3B), but the combin ion
of antibiotics with streptokinase almost completely removed the fibrin and eliminated the biofilm
(Figure 3C).
To test if a secondary non-fibrinolytic effect of streptokinase was at play, we grew biofilms in
tryptic soy br th in the absence of human plasma and pe formed MBEC assays with and wi out
streptokinase. These biofilms were deficient of fibrin and other human ECM proteins, and we confirmed
that streptokinase had no effect on the MBEC values (Table 2).
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Figure 3. Confocal Laser Scanning Microscopy (CLSM) imaging of USA300 biofilms grown in BHI
with plasma and Alexa Fluor conjugated fibrinogen. After 24 h growth, biofilms were incubated for
24 h in media (A), or media amended with vancomycin (4 mg/L) and rifampicin (10 mg/L) (B), or
media amended with vancomycin (4 mg/L) and rifampicin (10 mg/L) and streptokinase (500 U/mL)
(C). Alexa Fluor conjugated fibrinogen appear red, viable cells stained by SYTO 41 appear blue, and
dead cel s stained by TOTO®-1 app ar green, cyan, and yellow bec us some of these cells also bound
fibrinogen an SYTO 41. Blue arrows indicate cells that did not appear to bind fibrin gen, and pink
arrows indicate cells that bound fibrinogen and appeared to cause coagulation of fibrinogen to fibrin
fibers. Combination of antibiotics with streptokinase resulted in almost complete eradication of the
biofilm. A single viable cell that did not bind TOTO®-1 is indicated by the arrow. Scale bar = 20 µm.
Table 2. MBEC against biofilms of S. aureus USA 300 grown for 24 h in tryptic soy broth (TSB) and
incubated with antibiotics in the presence or absence of streptokinase. Rifampicin was added at a fixed
dosage of 10 mg/L.
Antibiotic MBEC (+Streptoki ase) (mg/L) MBEC (−Streptokinase) (mg/L)
Daptomycin + rifampicin >1024 >1024
Vancomycin + rifampicin >1024 >1024
4. Discussion
This study confirms that host-derived proteins are an integral part of the S. aureus USA300
biofilm matrix, and that fibrin provides a target for therapies that can potentiate the efficacy of
conventional antibiotics.
The addition of plasma to BHI stimulated biofilm formation immediately, and the large amount
of biofilm formed after the 2 h incubation period stresses that most of the biofilm was formed by the
aggregation of cells and coagulation of fibrin, rather than by growth. As expected, the biofilms were
rich in fibrin (Figure 3A,B), which extended as long fibers from the cell surface. Some cells, but not
all, were also coated with fluorescent fibrinogen that did not appear to take a fibrillar form (Figure 3,
blue and pink arrows). T is cell to cell ariation probably illustrates the variability in expression of
fibrinogen binding proteins, such as FnBPs, clumping factor, and SdrE. It is also interesting to note that
some of the dead cells, which were recognized by their ability to bind the membrane-impermeable
stain TOTO®-1 (green), also appeared to be a source of fibrin production. Many of these cells appear
yellow, as they also bind fibrinogen (red). This observation implies that dead cells may still be a source
of coagulase, and that the remains of these cells bind to fibrinogen and fibrin, and thereby become
integrated in the biofilm matrix.
Streptokinase only dispersed biofilms grown in BHI with plasma (Tables 1 and 2), and microscopy
confirmed that fibrinolysis was responsible for this effect, as fibrin was completely removed from the
biofilm after the addition of streptokinase (Figure 3). Streptokinase works by ctivating plasminogen
t plasmin by proteolysis, and the fibrinolytic effect is herefore dependent on the prese ce f
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plasminogen. The treatment of biofilms with antibiotics and streptokinase was performed in BHI
without plasma, and the available plasminogen must therefore be bound in the biofilm and transferred
from the previous incubation in BHI with 50% plasma. Plasminogen can be bound to S. aureus cells by
several mechanisms. Pietrocola et al. recently showed that FnBPB is responsible for binding the bulk of
plasminogen bound in the S. aureus biofilm matrix [37]. Furthermore, the manganese transport protein
C is also capable of binding a range of human extracellular matrix and coagulation cascade proteins,
including plasminogen [38]. This could explain why a sufficient amount of plasminogen was present to
induce fibrinolysis in the biofilm upon activation by streptokinase in BHI. The dose-dependent response
to increasing streptokinase concentrations even indicates that streptokinase and not plasminogen was
the limiting factor for the biofilm dispersal.
The antibiotic susceptibility of the biofilms appeared to be strongly affected by the composition
of the extracellular matrix. MBEC for vancomycin or daptomycin when combined with 10 mg/L
rifampicin were only 64 mg/L for biofilms grown in BHI with 50% plasma, but exceeded the 1024 mg/L
upper detection limit of the assay when biofilms were grown in TSB. This difference suggests that
the MBEC for biofilms in vivo may not be as high as predicted by measurements made in standard
laboratory media.
EDTA-stabilized plasma was chosen over heparin-stabilized plasma because previous studies
have shown that heparin can induce biofilm formation by S. aureus [39]. However, EDTA can also
induce adverse effects due to its toxicity. We used EDTA-stabilized plasma with a final EDTA
concentration of 0.9 mg/mL in media with 50% plasma, but the concentration of free EDTA was likely
much lower, as EDTA would be bound to components in the plasma. We confirmed that EDTA did not
inhibit biofilm growth of S. aureus USA300, and the concentration of free EDTA must therefore have
been below the MBC for this strain. Previous studies found a synergistic effect between antibiotics
and EDTA against S. aureus biofilms, but these results were obtained at 30 mg/mL EDTA [40,41].
We therefore argue that the theoretical maximum of 0.9 mg/mL EDTA in our study was unlikely to
have affected our results.
A natural limitation of our study is the ex vivo conditions, which raises the question of whether
one would expect to obtain a similar effect of streptokinase in vivo, because the effect may depend on
the biofilm thickness and architecture. Bjarnsholt et al. demonstrated that in vivo biofilms are generally
thinner than in vitro grown biofilms, and often contains only a few cell layers [42]. Our in vitro grown
biofilms were very thick and easily visible to the naked eye, and would therefore expect that the dose
of streptokinase used in our experiment would also be effective on in vivo grown biofilms. We were
able to fully disperse the biofilms (Figures 1 and 3) with a dosage of streptokinase that is many times
lower than the dosages used to treat patients with thromboembolic events. Hence, even if the dosage
used here is insufficient for dispersing in vivo grown biofilms, there is ample room for maneuvering
when adapting this approach to in vivo treatment.
An important question is also whether our observations apply generally to S. aureus, as the matrix
composition can vary from between strains, and the fibrin production is a balance between coagulase
activity and staphylokinase activity. In particular, the methicillin-resistant S. aureus used in this study
is known to rely more on proteins and less on polysaccharides compared to methicillin-sensitive
S. aureus [43]. However, several recent studies have confirmed the important role of fibrin for
methicillin-sensitive S. aureus biofilms in vivo [20,34], and that ex vivo treatment with fibrinolytic
drugs can disperse biofilms that are formed on implant surfaces in vivo [19].
To the best of our knowledge, our study demonstrates for first time that a drug combination
leads to eradication of mature biofilms at antibiotic concentrations that are achievable in patients.
Nemoto et al. demonstrated that streptokinase treatment in combination with ofloxacin reduced the
number of viable bacteria in S. aureus biofilms to less than 10% of tests with antibiotics alone [33].
However, this reduction was only achieved with a streptokinase dosage of 10,000 U/mL and an
ofloxacin concentration of 128 mg/L. While streptokinase can be administered at those concentrations,
the ofloxacin concentration far exceeds what is clinically possible [44]. Even at this high concentration,
biofilm eradication was not observed.
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We therefore hypothesized that the successful non-invasive eradication of S. aureus biofilms could
be achieved at physiologically relevant antibiotic concentrations if fibrinolytic drugs were combined
with the most effective combination of antibiotics. Indeed, we found no effect of streptokinase on
the MBEC for daptomycin, and only a 50% decrease of the MBEC for vancomycin when used as
single drugs. It was only when combining one of the antibiotics with rifampicin that streptokinase
treatment resulted in a dramatic decrease in the MBEC to clinically achievable levels. The maximum
recommended dose of daptomycin is 10 mg/kg, which results in a total in vivo concentration of
approximately 10–100 mg/L [45]. Current clinical guidelines recommend a trough concentration of
vancomycin of between 15–20 mg/L to avoid adverse events [46,47]. By combining a multi-drug
treatment, we show here that biofilm eradication could be achieved at 4 mg/L daptomycin or
vancomycin. As this concentration is easily achievable in vivo, our study provides an encouraging
lead for further investigation of using this drug combination to treat biofilm infections.
Our study demonstrated that good in vitro models are essential for investigating the role
of targeting the biofilm matrix to treat biofilm infections. We therefore stress the importance of
host-derived proteins for the structure and properties of the biofilm matrix, and propose that human
plasma is included as standard when growing Staphylococcus biofilms in vitro. If our findings are to be
applied to the treatment of biofilms in vivo, the use of fibronolytic drugs in conjunction with antibiotics
could improve treatment outcome for S. aureus biofilm infections. Prosthetic valve endocarditis caused
by S. aureus has a one-year mortality rate of 50% and even with surgery performed, re-infection rate is
about 6%–15% [48,49]. The need to improve the efficacy of antibiotic treatment is therefore critical, and
this study provides an important first step towards this goal.
5. Conclusions
In this study we demonstrated that adding human plasma to BHI increased biofilm formation by
S. aureus USA300. Mature S. aureus biofilms could be eradicated with clinically relevant concentrations
of daptomycin with rifampicin and vancomycin with rifampicin when treatment was concurrent with
clinically relevant dosages of streptokinase.
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